N-Linked Glycosylation in the Hemagglutinin of Influenza A Viruses

Jin Il Kim and Man-Seong Park
Department of Microbiology, Center for Medical Science Research, College of Medicine, Hallym University, Chuncheon, Korea.

Received: June 26, 2012
Corresponding author: Dr. Man-Seong Park, Department of Microbiology, Center for Medical Science Research, College of Medicine, Hallym University, 1 Hallymaehak-gil, Chuncheon 200-702, Korea. Tel: 82-33-248-2632, Fax: 82-33-252-2843 E-mail: ms0392@hallym.ac.kr

The authors have no financial conflicts of interest.

Since the 1918 influenza A virus (IAV) pandemic, H1N1 viruses have circulated in human populations. The hemagglutinin (HA) of IAV determines viral antigenicity and often undergoes N-linked glycosylation (NLG) at several sites. Interestingly, structural analysis of the 1918 and 2009 H1N1 pandemic viruses revealed antigenic similarities attributable to the conserved epitopes and the NLG statuses of their HA proteins. NLG of the globular head of HA is known to modulate the antigenicity, fusion activity, virulence, receptor-binding specificity, and immune evasion of IAV. In addition, the HA of IAV often retains additional mutations. These supplemental mutations compensate for the attenuation of viral properties resulting from the introduced NLG. In human H1N1 viruses, the number and location of NLG sites has been regulated in accordance with the antigenic variability of the NLG-targeted antibody-binding site. The relationship between the NLG and the antigenic variance in HA appears to be stably controlled in the viral context.

Key Words: Glycosylation, hemagglutinin, influenza virus, pandemic

INTRODUCTION

Ever since they adapted from waterfowl, various subtypes of the influenza A virus (IAV) have circulated in avian and mammalian hosts, including humans.1,2 There is a high level of antigenic variability, as shown by the recent discovery of the 17th hemagglutinin (HA) subtype in a virus from bats.3 Although most of the IAV-related disease burden in humans has been caused by the H1 and H3 subtypes, novel variants causing disease in humans can emerge at any time due to antigenic drift or shift.4 To reduce the number of infections due to this respiratory agent, the World Health Organization operates an interdisciplinary surveillance and countermeasures program in cooperation with more than 100 national influenza centers in six different regions (Africa, the Americas, Southeast Asia, the Eastern Mediterranean, Europe, and the Western Pacific), six collaborating centers, and four essential regulatory laboratories. This program largely focuses on the annual recommendation of candidate viruses for use in the inactivated trivalent influenza vaccine and also develops risk management protocols, such as ‘the pandemic influenza preparedness framework’ for emerging novel variants.5,6 A mismatch between vaccine vi-
Glycosylation of Influenza A Virus

1918 and 2009 pandemic viruses are notable exceptions (Fig. 1). In fact, the NLG of HA has been demonstrated to regulate the virulence of IAV by modulating the biological activity of HA. In addition, NLG can allow IAVs to evade antibody recognition. There have been reports that the NLG status of the receptor-binding domain mediated protective antibody responses to both the 1918 and 2009 pandemic H1N1 viruses and affected the immunogenic hierarchy in mouse antisera.

In this review, we discuss how the NLG of the globular head of HA affects the biological function of IAVs and how hH1N1 viruses utilize NLG for immune evasion.

Fig. 1. NLG of the globular head of H1 HA during each time period. Using the HA crystal structure of the A/California/04/2009 virus (PDB ID: 3LZG), the possible N-linked glycans on the head of H1 HA from Table 1 were evaluated. Potential glycosites (red) near the RBS (yellow) are indicated by the H3 numbering. NLG, N-linked glycosylation; HA, hemagglutinin; RBS, receptor-binding site.

THE HA PROTEIN AND ANTIGENIC VARIATION DUE TO NLG

HA, one of the major surface glycoproteins of IAV, com-

ruses and circulating strains can cause problems attributable to suboptimal vaccine efficacy and can result in greater disease severity, even among the vaccinated population. Thus, predicting the evolutionary pathway of HA is like a wheel of fortune. One of the most promising solutions to overcome this mismatch might be a universal vaccine with high cross-reactivity. Universal vaccines can overcome the difficulty in determining the appropriate vaccine virus and can promote the development of protective immunity against various IAVs. The conserved regions of HA are prime targets for the identification of universal epitope sequences. Even though vaccines targeting the neuraminidase (NA) or M2 proteins of IAVs have also been evaluated for broad reactivity, optimal antibody responses comparable to the response to natural infection were only obtained in the trials targeting HA.

Most human H1N1 (hH1N1) viruses harbor multiple N-linked glycosylation (NLG) sites in the head of HA; the
membranes the infection by binding to sialic acid (SA) moieties present on cell membranes. Once the virus is internalized by endocytosis, the protease-mediated cleavage of the HA protein into the HA1 and HA2 subunits exposes a hydrophobic fusion peptide located in the N-terminus of the HA2 subunit. The exposure of this peptide initiates a fusion process between the viral and cellular endosomal membranes. Then, the eight-segmented genome of IAV encapsidated by viral nucleocapsid protein is released into the cytoplasm for replication and transcription in the nucleus. This replication process is finally terminated by another surface glycoprotein, NA, which facilitates the release progeny virions that then infect neighboring cells.

In response to the immune pressure mediated by vaccination in humans, the HA of IAV often accumulates mutations that result in antigenic drift. Thus, viral evolution can be driven by antigenic variation. For some unknown reasons, the HA antigenic sites of hH1N1 viruses sometimes exhibit fewer amino acid changes. The number of potential NLG sites is also controlled in hH1N1 viruses. Five potential NLG sites in the head of each HA monomer are typically selected in hH1N1 viruses (Fig. 2). Only up to three out of the five glycosites are utilized (Table 1). Fitness costs might explain why IAVs never accept the total possible number of N-linked glycans on the head of HA. Interestingly, there might be a specific relationship between antigenic variation and the number and position of N-linked glycans on the globular head of HA in hH1N1 viruses. It is likely that the lower the number of N-linked glycans, the higher the total antigenic variability of the SA antigenic site in the HAs of hH1N1 viruses (Fig. 3).

**THE NLG OF THE HA OF IAV**

The NLG of glycoproteins takes place in both prokaryotic and eukaryotic cells. Through the attachment of glycans at asparagine residues, NLG promotes protein folding by en-
Glycosylation of Influenza A Virus

Table 1. Amino Acid Residues Harboring N-Linked Glycans on the Head of H1 HAs since the Early 1930s

| Time period       | Residues harboring NLG on the head of H1 HAs | Max. # of N-linked glycans |
|-------------------|---------------------------------------------|----------------------------|
| 1934-36           | 131                                         | 1                          |
| 1940-49           | 131                                         | 3                          |
| 1950-57           | 129*                                        | 3                          |
| 1977-85           | 131                                         | 3                          |
| 1986-97           | 129                                         | 3                          |
| 2000-08           | 129                                         | 2                          |
| Since 2009        | 165†                                        | 1                          |

NLG, N-linked glycosylation; HA, hemagglutinin; NCBI, National Center for Biotechnology Information.
This table was modified from Table 2 in the work of Wei, et al.19 published in 2010. The exceptional NLGs of residues 129 during 1950-57, 158 during 1977-85 and 1986-97, and 165 since 2009 were obtained from HA sequences available from the NCBI.

*GenBank accession ID: ADF17989.
†GenBank accession ID: ABF21277.
‡GenBank accession ID: ACE47164.
§GenBank accession ID: AE001518.

The NLG-regulated HA receptor-binding avidity and virulence of IAV

The NLG of the globular head of HA regulates the multivalent receptor-binding avidity of IAV to SA cellular receptors.34-40 In the hemadsorption assay, the presence of oligosaccharide side chains in the vicinity of the receptor-binding site (RBS) was shown to induce negative effects that interrupt the efficient HA and SA (HA-SA) interaction. When these N-linked glycans were removed, HA receptor-binding avidity was recovered, and erythrocytes were not released.38 It should be determined whether the strong receptor-bind-

Fig. 3. The antigenic variability and the number of N-linked glycans on the head (Sa antigenic site) of H1 HA. The variance in the amino acids (indicated at the left) in the Sa antigenic site of H1 HA was modified from the work of Wei, et al. published in 2012. For comparison, the numbers of N-linked glycans (indicated at the right) in the membrane-distal region of H1 HA were collected from the works of Wei, et al. and Sun, et al. and were supplemented with the HA sequences of the hH1N1 viruses available from the National Center for Biotechnology Information of the United States. NLG, N-linked glycosylation; HA, hemagglutinin.

hancing solubility and mediating interactions between nascent proteins and cellular proteins, such as chaperones.37 Three key processes in NLG have been identified: 1) the lipid-mediated assembly of monosaccharides into glycans, which is performed by various enzymes in the ER-Golgi network; 2) the acceptance of a glycan by the consensus sequence, N-X-S/T (Asn-X-Ser/Thr; X for any amino acid except proline), of the protein; and 3) the oligosaccharyltransferase-catalyzed attachment of the glycan to the side chain of the asparagine residue.36 The surface glycoproteins of influenza, HIV, and other important human pathogens adopt the NLG of the host cell. This process not only diversifies viral glycoproteins through the addition of various glycans but also conveniently allows the evasion of the host immune arsenal by sending ‘self signals’ to the innate immune machinery and by reducing the induction of antibodies against the viruses.25
ed viruses in MDCK cells, whereas mutant viruses with the weak N1 NA exhibited retarded growth. In addition, there seems to be a hierarchy among the glycosites around the RBS. Glycosite 149 (H3 numbering) was shown to more strongly regulate viral growth than glycosite 123 did, regardless of the relative NA activities. In a different study, the introduction of additional N-linked glycans around the RBS decreased both the receptor-binding and the fusogenic activities of HA and resulted in the retarded replication capacity of H2N2 viruses.

The virulence of IAV might also be regulated by NLG of the HA globular head region. In previous studies, an increased number of N-linked glycans attached to the head of HA attenuated the virulence of IAV in mice. In contrast, the loss of NLG increased the virulence of IAV. The augmented virulence during the adaptation of IAV in mice was also related to the removal of NLG sites in HA. However, innate immune responses were investigated primarily to elucidate the relationship between the virulence of IAV and NLG given that N-linked glycans had been previously shown to be targets of innate immunity. It has also been reported that enhanced resistance to surfactant protein-D and decreased susceptibility to collectins are associated with the loss of NLG and with elevated virulence in mice. According to all of these results, NLG of the membrane-distal region of HA has critical roles in the regulation of the biological activities of HA and the virus itself. In addition, the impact of NA activity and innate immune responses on NLG modification should also be considered to understand the effects of the presence or absence of NLG on the virulence of IAVs.

**THE NLG-MEDIATED ALTERATION OF HA RECEPTOR-BINDING SPECIFICITY**

Human IAV preferentially binds to α-2,6-sialic acid (6’ SA) moieties, whereas avian IAV favors α-2,3-sialic acid (3’ SA) in the cell membrane. It was previously revealed that the receptor binding specificity was primarily attributable to several amino acid residues, including 190, 226, and 228, in HA. The E190D mutation was demonstrated to be sufficient for a switch from avian to human receptor specificity (3’ SA→6’ SA) in the H1 subtype, and both the Q226L and G228S mutations were needed for the switching of the H2 and H3 subtypes. Hence, IAV requires adaptation to replicate effectively in new hosts, and these adaptations are usually accompanied by mutations around the RBS of HA. However, host adaptive mutations seem to emerge in a host cell-dependent manner. In an earlier study, a growth advantage was observed in Madin-Darby bovine kidney cells but not in chicken embryo fibroblast cells after the introduction of one mutation that removed the NLG site at residue 131 from the tip of the parental HA. In another study with the A/USSR/90/77 (H1N1) virus, host adaptation was associated with the alteration of receptor-binding specificity. The loss of the NLG site at residue 131 increased the binding affinity of the virus to 6’ SA, but there appeared to be no effect on the specificity for 3’ SA. When mapped in the HA crystal structure of A/Puerto Rico/8/34, glycosite 131 is located right next to the RBS. Due to the bulky side chains of oligosaccharides, NLG at this position might interfere heavily with the viral life cycle by blocking efficient access of HA to the SA receptor. As a result, this virus would require a breakthrough, such as an additional mutation, to survive, and the incorporation of such additional mutations might be a way for novel IAV variants to emerge. The HA of avian IAV prefers the 3’ SA receptor for cell binding. In a study of an H5N1 avian virus (A/Vietnam/1203/2004, VN1203), the T160A mutation in HA removed a potential NLG sequon at residue 158, but this mutation had no effect on the receptor preference of the virus. However, when compensated with the additional Q226L mutation, which is known to be one of the requirements for avian IAV to adapt to the 6’ SA of human receptors in H2 and H3 subtypes, the T160A/Q226L HA double mutants of the VN1203 virus exhibited altered receptor-binding specificity from 3’ SA to 6’ SA. The G158Q mutation was also demonstrated to control, in part, the receptor-binding preference of the parental A/WSN/33 strain and its N129D mutant viruses. These observations indicate that NLG itself might have a minor effect on the receptor-binding specificity of IAV. However, the steric interference caused by the attached N-linked glycans might induce viral compensations, which eventually result in altered receptor-binding specificity.

The relationship between changes in NLG and the transmissibility of IAV should be also considered. Given that the NLG of the globular head of HA can change the HA receptor-binding specificity, changes in NLG may modulate the transmissibility of IAV. In a guinea pig model, an H5N1 virus that could bind to both 3’ SA and 6’ SA lost its affinity for 6’ SA as a result of the A160T mutation, resulting in the complete loss of transmissibility of the parental virus. Thus, in addition to the alteration of receptor specificity, changes
in the NLG of the globular head of HA are able to affect viral transmission. Hence, changes in NLG should be monitored by continuous surveillance to prevent the transmission of emerging IAV variants.

**THE NLG-MEDIATED CIRCUMVENTION OF THE ANTIBODY RECOGNITION OF IAV**

The HA of hH1N1 viruses harbor multiple potential NLG sites in the head and stem regions. Unlike the stem region glycosites, each of the five glycosites (residues 129, 131, 158, 163, and 165) in the head of HA was selectively utilized for N-linked glycan attachment in hH1N1 viruses. By accepting the various changes in NLG, the hH1N1 viruses were able to shield the globular head region of HA and escape antibody recognition. The immune evasion mechanism has been studied using mutants that can escape monoclonal antibodies (MAbs). In a study with MAb 2D1, which was isolated from a survivor of the 1918 pandemic, the antibody recognition sites were usually matched with the Sa antigenic site at the tip of H1 HA. Considering the amino acid differences with respect to seasonal H1N1 viruses, NLG of the center of the Sa antigenic site might result in evasion from recognition by 2D1 for the seasonal H1N1 viruses. Another study with a 2009 pandemic-specific MAb, EM4C04, also suggested that NLG-mediated immune evasion could occur in response to the introduction of the K123N and G134S mutations. However, these NLG-mediated escape mutants might harbor compensatory mutations to maintain viral competence. It is possible that numerous quasispecies variants could emerge among the survivors of the antibody intervention. Among these variants, only a limited number of clones might maintain sufficient competence for survival. Mutations outside of the defined antigenic sites also yielded the same results. In a study with MAb 5J8, H1N1 HA retained mutations between the RBS and the Ca2 antigenic site. Although these mutations did not induce NLG-mediated evasion, the H1N1 viruses that survived might be supplemented with compensatory benefits. If these benefits have a high fitness cost, the viruses might choose an alternative, cost-effective path. For instance, the D199H mutation in the 1918 HA could not result in escape unless it was coupled with another mutation at residue 133a (147 in H1 numbering; K133aQ mutation), a compensatory change to maximize the effects of the D199H mutation. These results demonstrate that hH1N1 viruses accept mutations in response to antibody pressure, resulting in survival of the fittest virus.

**PERSPECTIVES**

IAV continuously evolves in various hosts. To achieve optimal competence against natural or transferred host immune responses, IAV adapts itself by modulating its viral properties. NLG of the globular head of HA is one of the tools used to evade immune pressure. By acquiring or losing NLG, IAV can circumvent direct or indirect interventions. In addition, the evolutionary signature of hH1N1 viruses might be embedded in the NLG attachment signal. As observed in the history of hH1N1 viruses, the HA of hH1N1 viruses have been never equipped with hyperglycosylation. Hence, there might be a balance between the number and location of NLG sites and the antigenic variance in the evolutionary pathway. NLG is certainly a viral countermeasure and should be understood in the comprehensive context of the virus itself and the immune interventions against it.

**ACKNOWLEDGEMENTS**

This study was supported by a grant from the Korea Healthcare Technology R&D Project of the Ministry of Health & Welfare, Republic of Korea (Grants No. A103001) and by the Hallym University Research Fund, 2007 (HRF-2007-043).

**REFERENCES**

1. Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 2010;7:440-51.
2. Salomon R, Webster RG. The influenza virus enigma. Cell 2009;136:402-10.
3. Tong S, Li Y, Rivailier P, Conrardy C, Castillo DA, Chen LM, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A 2012;109:4269-74.
4. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008;26 Suppl 4:D49-53.
5. WHO. Global influenza programme (GIP). Available from: www.who.int/influenza/en/index.html. Accessed in May 31, 2012.
6. Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukada K, et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influ-
enza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 2010;28:1156-67.

7. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000;61:94-9.

8. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007;25:6852-62.

9. Plotkin JB, Dushoff J, Levin SA. Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proc Natl Acad Sci U S A 2002;99:6263-8.

10. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006;12:61-5.

11. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011;162:19-30.

12. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011;333:850-6.

13. Fleishman SJ, Whitehead TA, Ekiert DC, Dreyfus C, Corn JE, Strauch EM, et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 2011;332:816-21.

14. Krause JC, Tishbane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE Jr. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 2011;85:10905-8.

15. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 2011;108:14216-21.

16. Kilbourne ED, Couch RB, Kasel JA, Keitel WA, Cate TR, Quares MJH, et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995;13:1799-803.

17. Neiryck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999;5:1157-63.

18. Nayak B, Kumar S, DiNapoli JM, Paldurai A, Perez DR, Collins PL, et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol 2010;84:2408-20.

19. Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, Kong WP, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010;2:24na21.

20. Sun S, Wang Q, Zhao F, Chen W, Li Z. Glycosylation site alteration in the evolution of influenza A (H1N1) viruses. PLoS One 2011;6:e22844.

21. Schulze IT. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis 1997;176 Suppl 1:S24-8.

22. Aytay S, Schulze IT. Single amino acid substitutions in the hemagglutinin can alter the host range and receptor binding properties of H1 strains of influenza A virus. J Virol 1991;65:3022-8.

23. Gambaryan AS, Marinina VP, Tuzikov AB, Bovin NV, Rudneva IA, Sinitsyn BV, et al. Effects of host-dependent glycosylation of hemagglutinin on receptor-binding properties on H1N1 human influenza A virus grown in MDCK cells and in embryonated eggs. Virology 1998;247:170-7.

24. Deshpande KL, Fried VA, Ando M, Webster RG. Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. Proc Natl Acad Sci U S A 1987;84:36-40.

25. Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 2007;15:211-8.

26. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 1984;81:1779-83.

27. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010;328:357-60.

28. Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infections: the contributions of virus and host factors. Curr Opin Immunol 2011;23:481-6.

29. Luo M. Influenza virus entry. Adv Exp Med Biol 2012;726:201-21.

30. Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 2001;260:171-90.

31. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993;67:2552-8.

32. Corti D, Suguitian AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010;120:1663-73.

33. Sun S, Wang Q, Zhao F, Chen W, Li Z. Prediction of biological functions on glycosylation site migrations in human influenza H1N1 viruses. PLoS One 2012;7:e32119.

34. Das SR, Puigbo P, Hensley SE, Hurt DE, Bennink JR, Yewdell JW. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog 2010;6:e1001211.

35. Das SR, Hensley SE, David A, Schmidt L, Gibbs JS, Puigbo P, et al. Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc Natl Acad Sci U S A 2011;108:E1417-22.

36. Schwarz F, Aebl M. Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol 2011;21:576-82.

37. Alberts B, Wilson JH, Hunt T. Molecular biology of the cell. 5th ed. New York: Garland Science; 2008.

38. Ohuchi M, Ohuchi R, Feldmann A, Klenk HD. Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety. J Virol 1997;71:8377-84.

39. Wagner R, Wolff T, Herwig A, Pleschka S, Klenk HD. Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J Virol 2000;74:6316-23.

40. Tsujiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, Li ZN, et al. Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the antigenic evolution of influenza virus A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J Gen Virol 2002;83(Pt 5):1137-46.

41. Vigerust DJ, Ulett KB, Boyd KL, Madsen J, Hawgood S, McCullers JA. N-linked glycosylation attenuates H3N2 influenza viruses. J Virol 2007;81:8593-80.
Glycosylation of Influenza A Virus

52. Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Castrucci MR, et al. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol 2000;74:8502-12.

53. Nobusawa E, Ishihara H, Morishita T, Sato K, Nakajima K. Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology 2000;278:587-96.

54. Crecelius DM, Deom CM, Schulze IT. Biological properties of a hemagglutinin mutant of influenza virus selected by host cells. Virology 1984;139:164-77.

55. Deom CM, Caton AJ, Schulze IT. Host cell-mediated selection of a mutant influenza A virus that has lost a complex oligosaccharide from the tip of the hemagglutinin. Proc Natl Acad Sci U S A 1986;83:3771-5.

56. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004;303:1838-42.

57. Wang W, Lu B, Zhou H, Suguitan AL Jr, Cheng X, Subbarao K, et al. Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. J Virol 2010;84:6570-7.

43. Reading PC, Pickett DL, Tate MD, Whitney PG, Job ER, Brooks AG. Loss of a single N-linked glycan from the hemagglutinin of influenza virus is associated with resistance to collectins and increased virulence in mice. Respir Res 2009;10:117.

44. Tate MD, Job ER, Brooks AG, Reading PC. Glycosylation of the hemagglutinin modulates the sensitivity of H3N2 influenza viruses to innate proteins in airway secretions and virulence in mice. Virology 2011;413:84-92.

45. Tate MD, Brooks AG, Reading PC. Specific sites of N-linked glycosylation on the hemagglutinin of H1N1 subtype influenza A virus determine sensitivity to inhibitors of the innate immune system and virulence in mice. J Immunol 2011;187:1884-94.

46. Rudneva IA, Ilyushina NA, Timofeeva TA, Webster RG, Kaverin NV. Restoration of virulence of escape mutants of H5 and H9 influenza viruses by their readaptation to mice. J Gen Virol 2005;86(Pt 10):2831-8.

47. O’Donnell CD, Vogel L, Wright A, Das SR, Wrammert J, Li GM, et al. Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice. MBio 2012;3. pii: e00120-12.

48. Reading PC, Tate MD, Pickett DL, Brooks AG. Glycosylation as a target for recognition of influenza viruses by the innate immune system. Adv Exp Med Biol 2007;598:279-92.

49. Rogers GN, D’Souza BL. Receptor binding properties of human and animal H1 influenza virus isolates. Virology 1989;173:317-22.

50. Connor RJ, Kawaoka Y, Webster RG, Paulson JC. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 1994;205:17-23.

51. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature 1983;304:76-8.